Journal of the American Chemical Society · 2015 · 34 citations · 46 references
Life SciencesBiochemistryMolecular BiologyProtein BiochemistryStructural BiochemistryStructural BiologyAmyloid FormationMacromolecular AssemblyMacromolecular StructurePeptide ChemistryProtein OligomerizationProtein StructureAmyloid Beta PeptidesAmyloid FibrilsAmyloid StructureAmyloidogenic PeptidesAmyloidogenic ProteinsBeta SheetsBeta-sheet ArchitectureMacrocyclic Peptides
Amyloid diseases such as Alzheimer's disease, Parkinson's disease, and type II diabetes share common features of toxic soluble protein oligomers. There are no structures at atomic resolution of oligomers formed by full-length amyloidogenic peptides and proteins, and only a few structures of oligomers formed by peptide fragments. The paucity of structural information provides a fundamental roadblock to understanding the pathology of amyloid diseases and developing preventions or therapies. Here, we present the X-ray crystallographic structures of three families of oligomers formed by macrocyclic peptides containing a heptapeptide sequence derived from the amyloidogenic E chain of β2-microglobulin (β2m). Each macrocyclic peptide contains the heptapeptide sequence β2m63-69 and a second heptapeptide sequence containing an N-methyl amino acid. These peptides form β-sheets that further associate into hexamers, octamers, and dodecamers: the hexamers are trimers of dimers; the octamers are tetramers of dimers; and the dodecamers contain two trimer subunits surrounded by three pairs of β-sheets. These structures illustrate a common theme in which dimer and trimer subunits further associate to form a hydrophobic core. The seven X-ray crystallographic structures not only illustrate a range of oligomers that a single amyloidogenic peptide sequence can form, but also how mutation can alter the size and topology of the oligomers. A cocrystallization experiment in which a dodecamer-forming peptide recruits a hexamer-forming peptide to form mixed dodecamers demonstrates that one species can dictate the oligomerization of another. These findings should also be relevant to the formation of oligomers of full-length peptides and proteins in amyloid diseases.
46
Amyloid Oligomers Exacerbate Tau Pathology in a Mouse Model of Tauopathy
Maj-Linda B. Selenica, Milene L. Brownlow, Jeffy P. Jimenez et al. · Neurodegenerative Diseases · 2012 · 10.4K citations · Full text
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Sylvain Lesné, Ming Teng Koh, Linda Kotilinek et al. · Nature · 2006 · 2.8K citations
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
James Cleary, Dominic M. Walsh, J. Hofmeister et al. · Nature Neuroscience · 2004 · 1.7K citations